Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of lenalidomide in patients with myelodysplastic syndrome (MDS) and
with acute myeloid leukemia (AML) with trilineage dysplasia. Patients will receive two cycles
of lenalidomide. Patients who respond may given additional cycles of lenalidomide until
disease progression.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins